MDM2 SNP309

CI-VAR-00004159Explore in graph →ClinVar 13904 CIViC 495 rs2279744

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Head and Neck Neoplasm1
MDM2 SNP309	(prognostic)	Prognostic	B	Supports Poor Outcome	2	accepted	EID1169 66 HNSCC patients treated with chemoradiation were assessed for survival after a follow-up time of 10 years. Median OS was significantly shorter in patients with MDM2 SNP309 GG or GT genotypes compare… (full text at CIViC) PMID 26916894 · Vivenza et al., 2016 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13904	Benign	criteria provided, multiple submitters, no conflicts	2	Accelerated tumor formation, susceptibility to	germline	3	Jan 05, 2026	clinvar